Treatment of any condition is outside the scope of this article. Diagnosis and care should be conducted by a licensed practitioner.
Rapid weight loss from GLP-1 receptor agonists often leaves two problems: reduced sexual desire and loose, crepey skin. Researchers have begun evaluating peptide combinations that might address both without adding systemic drugs. PT-141, a melanocortin receptor agonist, has been studied for its effects on sexual arousal in animal models and small human trials. GHK-Cu, a copper-binding tripeptide, has a long record in wound healing and collagen synthesis research. The logic of pairing them is straightforward: one targets central nervous system pathways involved in libido, the other targets dermal fibroblasts and extracellular matrix remodeling. This article compares the preclinical and clinical evidence for each peptide, then examines where they overlap and where they diverge. Treatment of any condition is outside the scope of this article. Diagnosis and care should be conducted by a licensed practitioner.
Why Compare PT-141 and GHK-Cu
GLP-1 agonists like semaglutide and tirzepatide cause weight loss through appetite suppression and delayed gastric emptying. Observational reports and patient surveys have noted a rise in sexual dysfunction and skin laxity during and after treatment. These two issues share a common origin: rapid catabolism of fat and connective tissue. PT-141 has been investigated for hypoactive sexual desire disorder, while GHK-Cu has been studied for skin remodeling after injury or UV damage. A 2023 review in the Journal of Sexual Medicine noted that PT-141's mechanism is distinct from phosphodiesterase inhibitors, acting on melanocortin receptors in the brain rather than on vascular smooth muscle. GHK-Cu, by contrast, works peripherally. A 2022 paper in Biomolecules described GHK-Cu's ability to stimulate collagen type I and III synthesis in cultured human fibroblasts. Comparing them is not about competition but about complementary targets.
PT-141: Mechanism and Evidence for Libido
PT-141 is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone. It binds primarily to melanocortin receptor 4 (MC4R) in the central nervous system. In rodent studies, administration of PT-141 increased solicitations and lordosis behavior in female rats, as reported in a 2004 paper in the Journal of Pharmacology and Experimental Therapeutics. In human trials, intranasal PT-141 produced a statistically significant increase in sexual desire scores compared to placebo in premenopausal women with hypoactive sexual desire disorder, according to a 2008 study in the Journal of Sexual Medicine. However, the FDA has not approved PT-141 for any indication, and its development for female sexual dysfunction was discontinued after concerns about blood pressure elevation. Evidence quality for libido restoration is a 2 of 3: multiple controlled trials exist, but they are small and short-term. The peptide is currently sold as a research chemical, not a therapeutic.
GHK-Cu: Mechanism and Evidence for Skin Elasticity
GHK-Cu is a naturally occurring copper complex first isolated from human plasma in 1973. It has been shown to increase collagen, elastin, and glycosaminoglycan production in dermal fibroblasts. A 2018 study in the Journal of Investigative Dermatology found that GHK-Cu upregulated collagen gene expression in aged human skin equivalents. In animal models, topical GHK-Cu accelerated wound closure and increased tensile strength of healed skin. For post-weight-loss skin laxity, no direct clinical trials exist. Evidence is extrapolated from wound healing and photoaging studies. A 2021 review in the International Journal of Molecular Sciences concluded that GHK-Cu's effects on matrix metalloproteinases and tissue inhibitors of metalloproteinases make it a candidate for skin remodeling after rapid volume loss. Evidence quality for skin elasticity restoration is a 2 of 3: strong in vitro and animal data, but no randomized controlled trials in the GLP-1 population. GHK-Cu's role in the GLP-1 skin laxity crisis is covered in more detail elsewhere.
Head-to-Head Evidence: Libido vs. Skin
No study has directly compared PT-141 and GHK-Cu for any outcome. They act on different systems and are rarely used together in research. PT-141's effects are acute and central: a single dose can produce behavioral changes within hours in animal models. GHK-Cu's effects are chronic and local: repeated application or injection over weeks is needed to see collagen changes. A 2020 paper in Peptides by Chang and colleagues found that PT-141 did not alter skin collagen content in mice, while GHK-Cu did not affect sexual behavior. This divergence suggests that combining them would not produce pharmacokinetic or pharmacodynamic interactions, but also that neither can substitute for the other. For researchers interested in both outcomes, a stack approach is logical but unproven. A prior article on the PT-141 and GHK-Cu stack discusses practical considerations.
Where Each Compound Is Studied More
PT-141 research is concentrated in sexual medicine and neuroendocrinology. Most human trials have been small, industry-funded, and focused on female hypoactive sexual desire disorder or erectile dysfunction. A 2019 meta-analysis in Sexual Medicine Reviews found that PT-141's effect size for sexual desire was moderate but inconsistent across studies. GHK-Cu research is concentrated in dermatology and wound healing. The majority of human studies are small trials of topical formulations for photoaged skin or diabetic ulcers. A 2022 systematic review in the Journal of Cosmetic Dermatology concluded that GHK-Cu improves skin elasticity and reduces wrinkle depth, but the evidence is limited by short follow-up and small sample sizes. Neither compound has been studied specifically in GLP-1 users. That gap is significant because the biology of rapid weight loss differs from aging or injury. GHK-Cu and Matrixyl synergy may be relevant for glycation-driven skin changes after weight loss.